236 related articles for article (PubMed ID: 18034590)
1. Pharmacotherapy for oesophagogastric cancer.
Jackson C; Starling N; Chua YJ; Cunningham D
Drugs; 2007; 67(17):2539-56. PubMed ID: 18034590
[TBL] [Abstract][Full Text] [Related]
2. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group.
Van Cutsem E; Van de Velde C; Roth A; Lordick F; Köhne CH; Cascinu S; Aapro M;
Eur J Cancer; 2008 Jan; 44(2):182-94. PubMed ID: 18093827
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
[TBL] [Abstract][Full Text] [Related]
4. The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial.
Tully R; Loughney L; Bolger J; Sorensen J; McAnena O; Collins CG; Carroll PA; Arumugasamy M; Murphy TJ; Robb WB;
Trials; 2020 Jul; 21(1):638. PubMed ID: 32660526
[TBL] [Abstract][Full Text] [Related]
5. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
Stahl M; Walz MK; Riera-Knorrenschild J; Stuschke M; Sandermann A; Bitzer M; Wilke H; Budach W
Eur J Cancer; 2017 Aug; 81():183-190. PubMed ID: 28628843
[TBL] [Abstract][Full Text] [Related]
6. Advanced gastric cancer: is there enough evidence to call second-line therapy standard?
Arkenau HT; Saggese M; Lemech C
World J Gastroenterol; 2012 Nov; 18(44):6376-8. PubMed ID: 23197882
[TBL] [Abstract][Full Text] [Related]
7. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
8. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
[TBL] [Abstract][Full Text] [Related]
9. Comparison of paclitaxel in combination with cisplatin (TP), carboplatin (TC) or fluorouracil (TF) concurrent with radiotherapy for patients with local advanced oesophageal squamous cell carcinoma: a three-arm phase III randomized trial (ESO-Shanghai 2).
Ai D; Chen Y; Liu Q; Zhang J; Deng J; Zhu H; Ren W; Zheng X; Li Y; Wei S; Ye J; Zhou J; Lin Q; Luo H; Cao J; Li J; Huang G; Wu K; Fan M; Yang H; Zhu Z; Zhao W; Li L; Fan J; Badakhshi H; Zhao K
BMJ Open; 2018 Oct; 8(10):e020785. PubMed ID: 30344165
[TBL] [Abstract][Full Text] [Related]
10. Management of esophageal cancer.
Ilson DH; Kelsen DP
Oncology (Williston Park); 1996 Sep; 10(9):1385-96, 1401-2; discussion 1402-8. PubMed ID: 8882928
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Hawkes E; Okines AF; Papamichael D; Rao S; Ashley S; Charalambous H; Koukouma A; Chau I; Cunningham D
Eur J Cancer; 2011 May; 47(8):1146-51. PubMed ID: 21269822
[TBL] [Abstract][Full Text] [Related]
12. A systematic overview of chemotherapy effects in breast cancer.
Bergh J; Jönsson PE; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936
[TBL] [Abstract][Full Text] [Related]
13. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
14. Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study.
Trip AK; Stiekema J; Visser O; Dikken JL; Cats A; Boot H; van Sandick JW; Jansen EP; Verheij M
Acta Oncol; 2015 Nov; 54(10):1754-62. PubMed ID: 25797568
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
16. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant therapy for oesophagogastric cancer.
Lordick F; Stein HJ; Peschel C; Siewert JR
Br J Surg; 2004 May; 91(5):540-51. PubMed ID: 15122603
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
19. Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes.
McNamara MJ; Adelstein DJ; Allende DS; Bodmann JW; Ives DI; Murthy SC; Raymond D; Raja S; Rodriguez CP; Sohal D; Stephans KL; Videtic GMM; Rybicki LA
J Gastrointest Cancer; 2017 Jun; 48(2):181-189. PubMed ID: 27734205
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
Athauda A; Watkins D; Mohammed K; Chau I; Starling N; Rao S; Tait D; Aitken K; Cunningham D
Anticancer Res; 2018 Oct; 38(10):5943-5949. PubMed ID: 30275223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]